Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.8
3.9
Journals
Sensors
Special Issues
New Features beyond Sudden Cardiac Death Prevention in Wearable and...
sensors-logo
Submit to Sensors Review for Sensors Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

New Features beyond Sudden Cardiac Death Prevention in Wearable and Implantable Defibrillators

A special issue of Sensors (ISSN 1424-8220). This special issue belongs to the section "Wearables".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 6902

Special Issue Editors

Prof. Dr. Christian Veltmann

E-Mail Website
Guest Editor
Elektrophysiologie Bremen, Bremen, Germany
Interests: sudden cardiac death; cardioverter–defibrillator; heart failure; primary electrical diseases
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. David Duncker

E-Mail Website
Guest Editor
Hannover Heart Rhythm Center, Department of Cardiology and Angiology, Hannover Medical School, 30625 Hannover, Germany
Interests: arrhythmias pacemakers; atrial fibrillation; heart failure; cardiac electrophysiology; cardiology chronic; electrocardiography; cardiomyopathies; cardiac function
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are glad to announce this Special Issue on the new features of wearable and implantable defibrillators beyond sudden cardiac death prevention. We invite you to contribute with original articles, reviews or meta-analyses.

Defibrillators are effective tools for preventing sudden cardiac death due to ventricular tachyarrhythmias. ICDs or WCD are indicated in patients with a permanent or temporary risk of ventricular tachyarrhythmias. Beyond sudden cardiac death protection the defibrillators now offer additional information. Biophysical data like heart rate, activity, posture, impedance, arrhythmia burden and other parameters can be monitored and guide the management of the patient. This special issue is dedicated, but not restricted to all the different facets of the implantable or wearable defibrillators: indications, patient outcomes, compliance, complications, and heart failure monitoring.

We are looking forward to your contribution.

Prof. Dr. Christian Veltmann
Dr. David Duncker
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Sensors is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • wearable cardioverter-defibrillator
  • implantable cardioverter-defibrillator
  • ICD
  • ventricular tachyarrhythmia
  • sudden cardiac death
  • heart failure
  • newly diagnosed heart failure
  • defibrillator shock

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 1754 KiB  
Article
Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiology—A PROLONG-II Substudy
by Johanna Mueller-Leisse, Johanna Brunn, Christos Zormpas, Stephan Hohmann, Henrike Aenne Katrin Hillmann, Jörg Eiringhaus, Johann Bauersachs, Christian Veltmann and David Duncker
Sensors 2022, 22(5), 2037; https://0-doi-org.brum.beds.ac.uk/10.3390/s22052037 - 05 Mar 2022
Cited by 3 | Viewed by 2393
Abstract
In patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF), three months of optimal therapy are recommended before considering a primary preventive implantable cardioverter-defibrillator (ICD). It is unclear which patients benefit from a prolonged waiting period under protection of the wearable [...] Read more.
In patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF), three months of optimal therapy are recommended before considering a primary preventive implantable cardioverter-defibrillator (ICD). It is unclear which patients benefit from a prolonged waiting period under protection of the wearable cardioverter-defibrillator (WCD) to avoid unnecessary ICD implantations. This study included all patients receiving a WCD for newly diagnosed HFrEF (n = 353) at our center between 2012 and 2017. Median follow-up was 2.7 years. From baseline until three months, LVEF improved in patients with all peripartum cardiomyopathy (PPCM), myocarditis, dilated cardiomyopathy (DCM), or ischemic cardiomyopathy (ICM). Beyond this time, LVEF improved in PPCM and DCM only (10 ± 8% and 10 ± 12%, respectively), whereas patients with ICM showed no further improvement. The patients with newly diagnosed HFrEF were compared to 29 patients with a distinct WCD indication, which is an explantation of an infected ICD. This latter group had a higher incidence of WCD shocks and poorer overall survival. All-cause mortality should be considered when deciding on WCD prescription. In patients with newly diagnosed HFrEF, the potential for delayed LVEF recovery should be considered when timing ICD implantation, especially in patients with PPCM and DCM. Full article
(This article belongs to the Special Issue New Features beyond Sudden Cardiac Death Prevention in Wearable and Implantable Defibrillators)
►▼ Show Figures

Figure 1

14 pages, 1770 KiB  
Article
Feasibility and First Results of Heart Failure Monitoring Using the Wearable Cardioverter–Defibrillator in Newly Diagnosed Heart Failure with Reduced Ejection Fraction
by Henrike Aenne Katrin Hillmann, Stephan Hohmann, Johanna Mueller-Leisse, Christos Zormpas, Jörg Eiringhaus, Johann Bauersachs, Christian Veltmann and David Duncker
Sensors 2021, 21(23), 7798; https://0-doi-org.brum.beds.ac.uk/10.3390/s21237798 - 23 Nov 2021
Cited by 7 | Viewed by 2153
Abstract
The wearable cardioverter–defibrillator (WCD) is used in patients with newly diagnosed heart failure and reduced ejection fraction (HFrEF). In addition to arrhythmic events, the WCD provides near-continuous telemetric heart failure monitoring. The purpose of this study was to evaluate the clinical relevance of [...] Read more.
The wearable cardioverter–defibrillator (WCD) is used in patients with newly diagnosed heart failure and reduced ejection fraction (HFrEF). In addition to arrhythmic events, the WCD provides near-continuous telemetric heart failure monitoring. The purpose of this study was to evaluate the clinical relevance of additionally recorded parameters, such as heart rate or step count. We included patients with newly diagnosed HFrEF prescribed with a WCD. Via the WCD, step count and heart rate were acquired, and an approximate for heart rate variability (HRV5) was calculated. Multivariate analysis was performed to analyze predictors for an improvement in left ventricular ejection fraction (LVEF). Two hundred and seventy-six patients (31.9% female) were included. Mean LVEF was 25.3 ± 8.5%. Between the first and last seven days of usage, median heart rate fell significantly (p < 0.001), while median step count and HRV5 significantly increased (p < 0.001). In a multivariate analysis, a delta of HRV5 > 23 ms was an independent predictor for LVEF improvement of ≥10% between prescription and 3-month follow-up. Patients with newly diagnosed HFrEF showed significant changes in heart rate, step count, and HRV5 between the beginning and end of WCD prescription time. HRV5 was an independent predictor for LVEF improvement and could serve as an early indicator of treatment response. Full article
(This article belongs to the Special Issue New Features beyond Sudden Cardiac Death Prevention in Wearable and Implantable Defibrillators)
►▼ Show Figures

Figure 1

10 pages, 1215 KiB  
Communication
Can Frailty Be a Predictor of ICD Shock after the Implantation of a Cardioverter Defibrillator in Elderly Patients?
by Agnieszka Mlynarska, Rafal Mlynarski, Bartosz Uchmanowicz and Wioletta Mikuľáková
Sensors 2021, 21(18), 6299; https://0-doi-org.brum.beds.ac.uk/10.3390/s21186299 - 20 Sep 2021
Cited by 3 | Viewed by 1696
Abstract
Introduction: The aim of the study was to assess the prevalence of frailty among elderly patients who had an implanted cardioverter defibrillator, as well as the influence of frailty on the main endpoints during the follow-up. Methods: The study included 103 patients > [...] Read more.
Introduction: The aim of the study was to assess the prevalence of frailty among elderly patients who had an implanted cardioverter defibrillator, as well as the influence of frailty on the main endpoints during the follow-up. Methods: The study included 103 patients > 60 years of age (85M, aged 71.56–8.17 years). All of the patients had an implanted single or dual-chamber cardioverter-defibrillator. In the research, there was a 12-month follow-up. The occurrence of frailty syndrome was assessed using the Tilburg Frailty Indicator scale (TFI). Results: Frailty syndrome was diagnosed in 75.73% of the patients that were included in the study. The mean values of the TFI were 6.55 ± 2.67, in the physical domain 4.06 ± 1.79, in the psychological domain 2.06 ± 1.10, and in the social domain 0.44 ± 0.55. During the follow-up period, 27.2% of patients had a defibrillator cardioverter electric shock, which occurred statistically more often in patients with diagnosed frailty syndrome (34.6%) compared to the robust patients (4%); p = 0.0062. In the logistic regression, frailty (OR: 1.203, 95% CI:1.0126–1.4298; p < 0.030) was an independent predictor of a defibrillator cardioverter electric shock. Similarly, in the logistic regression, frailty (OR: 1.3623, 95% CI:1.0290–1.8035; p = 0.019) was also an independent predictor for inadequate electric shocks. Conclusion: About three-quarters of the elderly patients that had qualified for ICD implantation were affected by frailty syndrome. In the frailty subgroup, adequate and inadequate shocks occurred more often compared to the robust patients. Full article
(This article belongs to the Special Issue New Features beyond Sudden Cardiac Death Prevention in Wearable and Implantable Defibrillators)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop